Tekla Capital Management LLC Genmab A/S Transaction History

Tekla Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$32.88 - $44.57 $2.4 Million - $3.25 Million	-73,015 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $5.74 Million - $8.24 Million	-185,657 Reduced 71.77%	73,015 $2.4 Million
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $2.49 Million - $3.01 Million	73,893 Added 39.99%	258,672 $10.5 Million
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $5.56 Million - $6.51 Million	168,259 Added 1018.52%	184,779 $6.77 Million
Q2 2020 Aug 13, 2020	SELL	$20.05 - $33.89 $2.64 Million - $4.46 Million	-131,628 Reduced 88.85%	16,520 $560,000
Q1 2020 May 14, 2020	BUY	$17.15 - $25.22 $2.26 Million - $3.32 Million	131,628 Added 796.78%	148,148 $3.14 Million
Q4 2019 Feb 13, 2020	BUY	$18.88 - $24.14 $311,897 - $398,792	16,520 New	16,520 $369,000

248

61.3M

159K

38K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $12.7B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.